Cao Huawei, Sun Zejia, Wu Jiyue, Hao Changzhen, Wang Wei
Department of Urology, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China.
Institute of Urology, Capital Medical University, Beijing, China.
Front Surg. 2022 Jul 5;9:894272. doi: 10.3389/fsurg.2022.894272. eCollection 2022.
Clear cell renal cell carcinoma (CCRCC) is a common urological neoplasm, and even though surgical resection is effective for localized CCRCC, the prognosis of metastatic CCRCC is poor. Currently, there is a paucity of recognized effective therapeutic protocols for metastatic CCRCC.
A 76-year-old Asian man underwent radical left nephrectomy for CCRCC 26 years ago; this patient visited our hospital with abdominal pain due to multiple abdominal metastases 24 years after the nephrectomy. After metastasectomy, he underwent targeted therapy combined with a programmed death receptor-1 (PD-1) inhibitor, and the current imaging results indicate remarkable tumor remission.
Metachronous pancreatic metastasis from CCRCC after nephrectomy is rare, but clinicians and patients should not ignore this possibility. The combination of targeted therapy and immunotherapy can result in satisfactory outcomes in cases where metastatic CCRCC continues to progress despite metastasectomy and targeted therapy. The combination of local and systemic therapy can be an effective therapeutic protocol for metastatic CCRCC, but there is no consensus on suitable therapeutics.
透明细胞肾细胞癌（CCRCC）是一种常见的泌尿系统肿瘤，尽管手术切除对局限性CCRCC有效，但转移性CCRCC的预后较差。目前，对于转移性CCRCC，缺乏公认的有效治疗方案。
一名76岁的亚洲男性26年前因CCRCC接受了根治性左肾切除术；肾切除术后24年，该患者因多处腹部转移瘤伴腹痛前来我院就诊。转移瘤切除术后，他接受了靶向治疗联合程序性死亡受体-1（PD-1）抑制剂治疗，目前的影像学结果显示肿瘤明显缓解。
肾切除术后CCRCC发生异时性胰腺转移罕见，但临床医生和患者不应忽视这种可能性。对于转移性CCRCC，尽管已进行转移瘤切除术和靶向治疗仍持续进展的病例，靶向治疗与免疫治疗联合可产生满意的效果。局部治疗与全身治疗联合可能是转移性CCRCC的有效治疗方案，但对于合适的治疗方法尚无共识。
